Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : DRW Venture Capital LLC
Deal Size : $10.8 million
Deal Type : Financing
DelSiTech Closes EUR 10 Million Financing Round for Drug Delivery Technology
Details : Proceeds will support clinical development of DST1308, using a silica-based drug delivery platform, for Chronic Hepatitis B.
Brand Name : DST1308
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : DRW Venture Capital LLC
Deal Size : $10.8 million
Deal Type : Financing
Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AB-729 is a subcutaneously-delivered RNAi therapeutic specifically designed to reduce all HBV viral antigens, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to virus.
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to...
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 20, 2022
Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
Details : ABI-H0731 (Vebicorvir), is a first-generation core inhibitors has been shown to be well-tolerated and statistically superior in antiviral activity in hepatitis B virus DNA suppression.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2022
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,Entecavir,Pegylated-interferon Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
Details : ABI-H0731, a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity in chronic hepatitis B (CHB) patients also exhibited selective inhibition of HBV DNA replication.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2021
Lead Product(s) : Vebicorvir,Entecavir,Pegylated-interferon Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ABI-H2158,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158
Details : The Phase 2 clinical study for ABI-H2158 is a multi-center, randomized, placebo-controlled trial in treatment-naïve patients with HBeAg positive or HBeAg negative chronic hepatitis B infection without cirrhosis.
Brand Name : ABI-H2158
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 01, 2021
Lead Product(s) : ABI-H2158,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : BeiGene
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2021
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : BeiGene
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,GalNAc-RNAi,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Assembly Biosciences is foregoing its plans to initiate Phase 3 registrational studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST) to concentrate its research and development efforts on finite and curative HBV therapies.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 25, 2021
Lead Product(s) : Vebicorvir,GalNAc-RNAi,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,Tenofovir Alafenamide,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In Phase 2 clinical trials, first-generation core inhibitor vebicorvir administered with nucleos(t)ide analogue reverse transcriptase inhibitor therapy has been well-tolerated, has shown statistically superior antiviral activity in HBV DNA suppression to...
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2020
Lead Product(s) : Vebicorvir,Tenofovir Alafenamide,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Assembly’s novel core inhibitor vebicorvir in combination with standard-of-care NrtI continues to demonstrate a favorable safety and tolerability profile, with no observed treatment-emergent resistance in patients with HBeAg negative chronic HBV infect...
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 28, 2020
Lead Product(s) : Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?